Aridis Pharmaceuticals, Inc. (ARDS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -29.99 Million USD | 31.38% |
| 2021 | -43.71 Million USD | -95.13% |
| 2020 | -22.4 Million USD | 22.99% |
| 2019 | -29.08 Million USD | -20.61% |
| 2018 | -24.11 Million USD | -22.19% |
| 2017 | -19.73 Million USD | -150.36% |
| 2016 | -7.88 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q3 | -869 Thousand USD | -106.36% |
| 2023 Q2 | 13.66 Million USD | 318.25% |
| 2023 Q1 | -6.26 Million USD | 15.59% |
| 2022 Q1 | -7.42 Million USD | 25.53% |
| 2022 FY | -29.99 Million USD | 31.38% |
| 2022 Q3 | -7.41 Million USD | 4.2% |
| 2022 Q2 | -7.73 Million USD | -4.22% |
| 2022 Q4 | -7.42 Million USD | -0.11% |
| 2021 FY | -43.71 Million USD | -95.13% |
| 2021 Q2 | -6.23 Million USD | 9.64% |
| 2021 Q1 | -6.89 Million USD | -18.48% |
| 2021 Q4 | -9.96 Million USD | 52.59% |
| 2021 Q3 | -21.02 Million USD | -237.28% |
| 2020 Q1 | -6.55 Million USD | -15.24% |
| 2020 Q4 | -5.82 Million USD | -0.54% |
| 2020 Q3 | -5.79 Million USD | -36.93% |
| 2020 FY | -22.4 Million USD | 22.99% |
| 2020 Q2 | -4.23 Million USD | 35.48% |
| 2019 Q3 | -7.39 Million USD | 10.54% |
| 2019 Q1 | -7.73 Million USD | -38.73% |
| 2019 FY | -29.08 Million USD | -20.61% |
| 2019 Q4 | -5.68 Million USD | 23.07% |
| 2019 Q2 | -8.26 Million USD | -6.84% |
| 2018 Q2 | -4.55 Million USD | 38.26% |
| 2018 FY | -24.11 Million USD | -22.19% |
| 2018 Q4 | -5.57 Million USD | 15.76% |
| 2018 Q3 | -6.62 Million USD | -45.49% |
| 2018 Q1 | -7.37 Million USD | -65.51% |
| 2017 Q1 | -5.82 Million USD | 0.0% |
| 2017 Q2 | -3.97 Million USD | 31.7% |
| 2017 Q3 | -5.48 Million USD | -37.94% |
| 2017 Q4 | -4.45 Million USD | 18.83% |
| 2017 FY | -19.73 Million USD | -150.36% |
| 2016 FY | -7.88 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -5988.169% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -215.119% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 55.33% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -89.314% |
| Better Therapeutics, Inc. | -38.26 Million USD | 21.612% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 28.714% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -150.568% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 11.379% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 12.859% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 72.348% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -1389.002% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 11.79% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 36.119% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -2093.455% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -50.422% |
| Molecular Templates, Inc. | -10.46 Million USD | -186.576% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -113.46% |
| NexImmune, Inc. | -29.19 Million USD | -2.742% |
| Orgenesis Inc. | -53.63 Million USD | 44.08% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 41.527% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -38344.185% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -85.77% |
| Scopus BioPharma Inc. | -11.71 Million USD | -156.025% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 94.053% |
| Statera Biopharma, Inc. | -98.34 Million USD | 69.502% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -334.807% |
| Trevena, Inc. | -35.28 Million USD | 15.005% |
| Vaxxinity, Inc. | -58.28 Million USD | 48.541% |
| Vaccinex, Inc. | -22.88 Million USD | -31.06% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -2764.721% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 40.834% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -312.955% |